Elesclomol's Phase III Fizzle Leaves Synta In Need Of Alternatives
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Suspension of Synta/GlaxoSmithKline's Phase III oncology candidate elesclomol amid signs of higher mortality has left developer Synta with a gaping late-stage pipeline hole and in need of a new business plan